Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...
This November, the nonprofit I AM ALS is launching a peer support program as part of its new campaign focused on supporting ...
The University of Ghana (UG), in collaboration with Google Research Africa and the University College of London’s (UCL) ...
In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...
The funding will help support the Ontario Provincial ALS Program to meet the needs of the roughly 1,300 people in Ontario ...
Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...
Ben Baldanza, who helped pioneer discount air travel as head of Spirit Airlines Inc. and became a target of passenger ...
ARLINGTON, Virginia—Ben Baldanza, former president and CEO of U.S. ULCC Spirit Airlines, died Nov. 5 after a long battle with ...
Benzinga on MSN2d
NeuroSense Moves Toward Early Commercialization Of ALS Treatment In Canada, Eyeing $100M+ MarketNeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company developing novel treatments for severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback